Trimethadione
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 3,5,5-trimethyl-1,3-oxazolidine-2,4-dione | |
| Clinical data | |
| Trade names | Tridione |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | X |
| Legal status | ℞ Prescription only |
| Routes | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half-life | ? |
| Excretion | ? |
| Identifiers | |
| CAS number | 127-48-0  |
| ATC code | N03AC02 |
| PubChem | CID 5576 |
| DrugBank | APRD00315 |
| ChemSpider | 5374 |
| UNII | R7GV3H6FQ4 |
| KEGG | D00392 |
| ChEMBL | CHEMBL695 |
| Chemical data | |
| Formula | C6H9NO3 |
| Mol. mass | 143.141 g/mol |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Trimethadione is an oxazolidinedione anticonvulsant. It is most commonly used to treat epileptic conditions that are resistant to other treatments.
Contents |
[edit] Fetal trimethadione syndrome
If administered during pregnancy, fetal trimethadione syndrome may result causing facial dysmorphism (short upturned nose, slanted eyebrows), cardiac defects, intrauterine growth retardation (IUGR), and mental retardation. The fetal loss rate while using trimethadione has been reported to be as high as 87%.[1]
[edit] Chemistry
Trimethadione, 3,5,5-trimethyloxazolidine-2,4-dione, may be synthesized by methylating 5,5-trimethyloxazolidine-2,4-dione with dimethylsulfate. Starting 5,5-trimethyloxazolidine-2,4-dione is in turn synthesized by the cyclocondensation of the ester of 2-hydroxyisobutyric acid with urea.
- J.S.H. Davies, W. Hook, U.S. Patent 2,559,011 (1951).
- M.A. Spielman, U.S. Patent 2,575,692 (1951).
- Spielman, M. A. (1944). Journal of the American Chemical Society 66 (8): 1244–1245. doi:10.1021/ja01236a005.
[edit] References
- ^ Teratology and Drug Use During Pregnancy Retrieved January 2007
[edit] External links
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
